肝癌患者-话题@MedSci

#肝癌患者#

80篇内容 | 2254人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1969020, encodeId=75df196902087, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=JAMA Surg：肝癌患者术后晚期复发的影响因素研究, objectType=article, longId=153511, objectId=2a4115351145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a4115351145, replyNumber=0, likeNumber=65, createdTime=2019-06-12, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a4115351145, moduleTitle=JAMA Surg：肝癌患者术后晚期复发的影响因素研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a4115351145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969027, encodeId=a880196902edd, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率, objectType=article, longId=172162, objectId=ddb51e2162bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb51e2162bf, replyNumber=0, likeNumber=62, createdTime=2019-11-22, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb51e2162bf, moduleTitle=与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb51e2162bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969021, encodeId=83ef196902129, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=抗击肝癌治疗“寒冬僵局” 中国肝癌患者将迎治疗春天, objectType=article, longId=156634, objectId=d1af15663476, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1af15663476, replyNumber=0, likeNumber=74, createdTime=2019-11-02, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1af15663476, moduleTitle=抗击肝癌治疗“寒冬僵局” 中国肝癌患者将迎治疗春天, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1af15663476)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969024, encodeId=1938196902414, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=2019 ASCO：CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益, objectType=article, longId=168585, objectId=f0091685856a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0091685856a, replyNumber=0, likeNumber=0, createdTime=2019-09-29, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0091685856a, moduleTitle=2019 ASCO：CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0091685856a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969017, encodeId=cd8c196901ead, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=全世界有一半的肝癌患者在中国,免疫治疗能治好肝癌吗?, objectType=article, longId=145571, objectId=1c471455e1a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c471455e1a7, replyNumber=0, likeNumber=68, createdTime=2019-04-23, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c471455e1a7, moduleTitle=全世界有一半的肝癌患者在中国,免疫治疗能治好肝癌吗?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c471455e1a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969018, encodeId=65af1969018d3, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatology：在中-晚期肝癌患者中，肝切除和化疗栓塞两种治疗方法的比较, objectType=article, longId=149807, objectId=315514980e34, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=315514980e34, replyNumber=0, likeNumber=84, createdTime=2018-10-14, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=315514980e34, moduleTitle=Hepatology：在中-晚期肝癌患者中，肝切除和化疗栓塞两种治疗方法的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=315514980e34)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969016, encodeId=a2ab196901634, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益, objectType=article, longId=139468, objectId=ee9013946879, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee9013946879, replyNumber=0, likeNumber=91, createdTime=2018-06-13, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee9013946879, moduleTitle=秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee9013946879)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969019, encodeId=b860196901957, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=复旦中山医院突破黄疸禁区巨型肝癌患者获救, objectType=article, longId=151747, objectId=8f4e151e473d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f4e151e473d, replyNumber=0, likeNumber=66, createdTime=2018-11-11, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f4e151e473d, moduleTitle=复旦中山医院突破黄疸禁区巨型肝癌患者获救, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8f4e151e473d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969015, encodeId=8fb4196901573, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低, objectType=article, longId=138154, objectId=208313815466, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208313815466, replyNumber=0, likeNumber=62, createdTime=2018-05-15, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208313815466, moduleTitle=Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208313815466)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969011, encodeId=3fef19690114b, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatology：在治疗中晚期肝癌患者中，原发性肝切除术(PH)优于经动脉化疗栓塞(TACE), objectType=article, longId=132930, objectId=3f1b13293054, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f1b13293054, replyNumber=0, likeNumber=77, createdTime=2018-03-23, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f1b13293054, moduleTitle=Hepatology：在治疗中晚期肝癌患者中，原发性肝切除术(PH)优于经动脉化疗栓塞(TACE), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f1b13293054)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969010, encodeId=53ed19690108d, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=J Hepatol：正电子发射断层摄影术与18F -氟化氢的计算机断层摄影术可以改善肝癌患者的肿瘤分期和治疗配置, objectType=article, longId=132758, objectId=8097132e58f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8097132e58f8, replyNumber=0, likeNumber=86, createdTime=2018-05-20, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8097132e58f8, moduleTitle=J Hepatol：正电子发射断层摄影术与18F -氟化氢的计算机断层摄影术可以改善肝癌患者的肿瘤分期和治疗配置, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8097132e58f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969014, encodeId=dea319690148d, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatology：晚期肝癌患者需要个体化治疗, objectType=article, longId=137610, objectId=693813e61075, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693813e61075, replyNumber=0, likeNumber=61, createdTime=2018-09-03, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693813e61075, moduleTitle=Hepatology：晚期肝癌患者需要个体化治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693813e61075)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969012, encodeId=61eb196901285, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatology：预防肝癌患者TACE引发的不良事件不妨试试这个方案, objectType=article, longId=133165, objectId=63b7133165fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63b7133165fc, replyNumber=0, likeNumber=66, createdTime=2018-10-10, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63b7133165fc, moduleTitle=Hepatology：预防肝癌患者TACE引发的不良事件不妨试试这个方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63b7133165fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969013, encodeId=ca1a19690131d, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Cyramza可改善晚期肝癌患者的存活率, objectType=article, longId=134489, objectId=a62013448915, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a62013448915, replyNumber=0, likeNumber=76, createdTime=2019-01-19, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a62013448915, moduleTitle=Cyramza可改善晚期肝癌患者的存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a62013448915)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969009, encodeId=44ef1969009b4, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=J Gastrointest Surg：肿瘤负担评分（TBS）可用于肝癌患者的预后分层, objectType=article, longId=130434, objectId=2d3f130434fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d3f130434fc, replyNumber=0, likeNumber=66, createdTime=2018-04-20, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d3f130434fc, moduleTitle=J Gastrointest Surg：肿瘤负担评分（TBS）可用于肝癌患者的预后分层, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d3f130434fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969003, encodeId=ba771969003c1, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Aliment Pharmacol Ther：索拉非尼的毒性可预测肝癌患者生存率改善, objectType=article, longId=98558, objectId=f76f9855801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f76f9855801, replyNumber=0, likeNumber=82, createdTime=2017-12-23, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f76f9855801, moduleTitle=Aliment Pharmacol Ther：索拉非尼的毒性可预测肝癌患者生存率改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f76f9855801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969008, encodeId=462d19690080e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=重磅！多纳非尼可显著延长晚期不可手术肝癌患者生命, objectType=article, longId=114742, objectId=353c114e42ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=353c114e42ba, replyNumber=0, likeNumber=59, createdTime=2018-05-15, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=353c114e42ba, moduleTitle=重磅！多纳非尼可显著延长晚期不可手术肝癌患者生命, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=353c114e42ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969000, encodeId=40e7196900018, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=Hepatology：王红阳院士发现肝癌患者中红细胞增多症的分子机制, objectType=article, longId=83548, objectId=236a835483a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236a835483a, replyNumber=0, likeNumber=72, createdTime=2017-02-06, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236a835483a, moduleTitle=Hepatology：王红阳院士发现肝癌患者中红细胞增多症的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=236a835483a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969005, encodeId=b0c61969005eb, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=90%肝癌患者伴有乙肝！肝癌不传染但肝炎传染啊…, objectType=article, longId=102006, objectId=ff67102006cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff67102006cb, replyNumber=0, likeNumber=88, createdTime=2018-05-17, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff67102006cb, moduleTitle=90%肝癌患者伴有乙肝！肝癌不传染但肝炎传染啊…, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff67102006cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1969007, encodeId=7471196900e0b, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, objectTitle=世界每年新增肝癌患者70万，中国占一半！你“肝”净吗, objectType=article, longId=103429, objectId=be6e10342911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be6e10342911, replyNumber=0, likeNumber=61, createdTime=2017-07-04, rootId=0, userName=zhu_jun9837, userId=3609256, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be6e10342911, moduleTitle=世界每年新增肝癌患者70万，中国占一半！你“肝”净吗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be6e10342911)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肝癌患者

2020-05-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

JAMA Surg：肝癌患者术后晚期复发的影响因素研究

2019-06-12

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

与索拉非尼相比，Opdivo无法显著提高肝癌患者的生存率

2019-11-22

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

抗击肝癌治疗“寒冬僵局” 中国肝癌患者将迎治疗春天

2019-11-02

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

2019 ASCO：CheckMate 040再续经典，O+Y首次被证实为晚期肝癌患者带来显著获益

2019-09-29

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

全世界有一半的肝癌患者在中国,免疫治疗能治好肝癌吗?

2019-04-23

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatology：在中-晚期肝癌患者中，肝切除和化疗栓塞两种治疗方法的比较

2018-10-14

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

秦叔逵教授：见证肝癌治疗里程碑，Ramucirumab可为高AFP肝癌患者带来生存获益

2018-06-13

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

复旦中山医院突破黄疸禁区巨型肝癌患者获救

2018-11-11

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Liver Int：与病毒性HCC患者相比，隐型肝癌患者的肿瘤更大，肿瘤分期愈晚，总体生存率较低

2018-05-15

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatology：在治疗中晚期肝癌患者中，原发性肝切除术(PH)优于经动脉化疗栓塞(TACE)

2018-03-23

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

J Hepatol：正电子发射断层摄影术与18F -氟化氢的计算机断层摄影术可以改善肝癌患者的肿瘤分期和治疗配置

2018-05-20

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatology：晚期肝癌患者需要个体化治疗

2018-09-03

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatology：预防肝癌患者TACE引发的不良事件不妨试试这个方案

2018-10-10

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Cyramza可改善晚期肝癌患者的存活率

2019-01-19

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

J Gastrointest Surg：肿瘤负担评分（TBS）可用于肝癌患者的预后分层

2018-04-20

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Aliment Pharmacol Ther：索拉非尼的毒性可预测肝癌患者生存率改善

2017-12-23

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

重磅！多纳非尼可显著延长晚期不可手术肝癌患者生命

2018-05-15

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

Hepatology：王红阳院士发现肝癌患者中红细胞增多症的分子机制

2017-02-06

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

90%肝癌患者伴有乙肝！肝癌不传染但肝炎传染啊…

2018-05-17

zhu_jun9837 (审核中...)

前往app查看评论内容

#肝癌患者#

世界每年新增肝癌患者70万，中国占一半！你“肝”净吗

2017-07-04

科室
- - 订阅+
  - 更多科室
工具
服务